1. Scrip
  2. >>Business

Finance Watch: VC Fundraising Dips In Q2, But Mega-Deal Pace Is Strong

First Half Of 2022 Venture Cash Equals 2019 Full-Year Total

 
• By Mandy Jackson and Ayisha Sharma

Private Company Edition: The amount of venture capital raised by biopharma firms fell but individual companies grabbed a lot of cash, making for a remarkable Q2 relative to pre-pandemic times. Recent Q3 rounds includes Frontera’s $160m series B. Also, Oxford Science Enterprises added €250m to its fund.

Finance Watch Private Company
• Source: Shutterstock

Venture capital fundraising by biopharmaceutical firms in the second quarter was a mixed bag, according to Venture Monitor data from Pitchbook and the National Venture Capital Association (NVCA), which reported a sharp drop from Q1 to Q2 in terms of both the amount of money raised and the number of companies that closed VC rounds, but a big gain in the average deal size.

In the second quarter, 210 biopharma companies raised $6.1bn, down from 302 companies that raised $11.6bn in the first quarter, and below the $9.7bn raised in Q2 of 2021 and $6.4bn in Q2 of 2020. But to put those numbers in perspective, both 2020 and 2021 were record years for venture capital fundraising by a wide margin

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.